Cover Image

Antibody-Drug Conjugates and Immunotoxins From Pre-Clinical Development to Therapeutic Applications /

The concept of delivering magic bullets to treat diseases was first proposed by Paul Erlich in the early 1900s.� The realization of this concept for the treatment of cancer occurred in the late 1990s with the approval of monoclonal antibody therapies.� The use of monoclonal antibodies conjugated...

Full description

Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Phillips, Gail Lewis. (Editor)
Format: Electronic
Language:English
Published: New York, NY : Springer New York : Imprint: Springer, 2013.
Series:Cancer Drug Discovery and Development
Subjects:
Medicine.
Oncology.
Monoclonal antibodies.
Biomedicine.
Cancer Research.
Biomedicine general.
Antibodies.
Online Access:https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-1-4614-5456-4
Table of Contents:
  • Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins
  • Antibody-Drug Conjugate Development
  • Components of ADC Development: Assay Methodologies and Challenges
  • Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates
  • Predictive Biomarkers for Antibody-Drug Conjugates
  • Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates
  • Linker Technology and Impact of Linker Design on ADC Properties
  • Antibody-drug conjugates for the treatment of B-cell malignancies
  • Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies
  • Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies
  • Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer
  • CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)
  • Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer
  • EphA2 Immunoconjugate
  • Anti-PSMA Antibody-Drug Conjugates
  • Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine
  • Studies on the Metabolism of Antibody-Drug Conjugates
  • Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu
  • The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors
  • Index.

Similar Items